Latanoprost Reduces Vision Loss Risk in Glaucoma

Article

Latanoprost eye drops may significantly reduce the risk of vision loss in patients with glaucoma.

Latanoprost eye drops may significantly reduce the risk of vision loss in patients with glaucoma, a new study indicates.

The study, published online on December 18, 2014, in The Lancet, examined the outcomes of more than 500 newly diagnosed glaucoma patients.

The research team found that patients who were given latanoprost, a prostaglandin analogue eye drop, experienced a >50% reduced risk of vision loss over 2 years compared with the placebo group.

“Medication to lower raised eye pressure has been used for decades as the main treatment for open-angle glaucoma to delay progressive vision loss," said lead study author, David Garway-Heath, in a press release. "But, until now, the extent to which the most frequently prescribed class of pressure-lowering drugs (prostaglandin analogues) have a protective effect on vision was not known.”

Garway-Heath continued that the research team’s findings “offer solid proof to patients and practitioners that the visual deterioration caused by glaucoma can be reduced using this treatment.”

Related Videos
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.